Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $20.68 million. The enterprise value is $12.67 million.
Important Dates
The next confirmed earnings date is Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 10.19 million shares outstanding. The number of shares has increased by 13.40% in one year.
| Current Share Class | 9.91M |
| Shares Outstanding | 10.19M |
| Shares Change (YoY) | +13.40% |
| Shares Change (QoQ) | -17.22% |
| Owned by Insiders (%) | 9.17% |
| Owned by Institutions (%) | 8.80% |
| Float | 6.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.19 |
| Forward PS | 0.31 |
| PB Ratio | 0.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.19 |
| EV / EBITDA | 1.60 |
| EV / EBIT | 4.99 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 1.21.
| Current Ratio | 1.26 |
| Quick Ratio | 0.98 |
| Debt / Equity | 1.21 |
| Debt / EBITDA | 2.68 |
| Debt / FCF | n/a |
| Interest Coverage | 0.69 |
Financial Efficiency
Return on equity (ROE) is -60.76% and return on invested capital (ROIC) is 3.69%.
| Return on Equity (ROE) | -60.76% |
| Return on Assets (ROA) | 1.31% |
| Return on Invested Capital (ROIC) | 3.69% |
| Return on Capital Employed (ROCE) | 4.15% |
| Revenue Per Employee | $799,783 |
| Profits Per Employee | -$163,398 |
| Employee Count | 83 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.74 |
Taxes
In the past 12 months, Aytu BioPharma has paid $437,000 in taxes.
| Income Tax | 437,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.33% in the last 52 weeks. The beta is 0.29, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | +10.33% |
| 50-Day Moving Average | 2.23 |
| 200-Day Moving Average | 1.85 |
| Relative Strength Index (RSI) | 38.69 |
| Average Volume (20 Days) | 85,428 |
Short Selling Information
The latest short interest is 612,597, so 6.01% of the outstanding shares have been sold short.
| Short Interest | 612,597 |
| Short Previous Month | 604,226 |
| Short % of Shares Out | 6.01% |
| Short % of Float | 9.49% |
| Short Ratio (days to cover) | 1.63 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $66.38 million and -$13.56 million in losses. Loss per share was -$2.16.
| Revenue | 66.38M |
| Gross Profit | 45.83M |
| Operating Income | 2.54M |
| Pretax Income | -13.75M |
| Net Income | -13.56M |
| EBITDA | 7.91M |
| EBIT | 2.54M |
| Loss Per Share | -$2.16 |
Full Income StatementBalance Sheet
The company has $30.95 million in cash and $22.94 million in debt, giving a net cash position of $8.02 million or $0.79 per share.
| Cash & Cash Equivalents | 30.95M |
| Total Debt | 22.94M |
| Net Cash | 8.02M |
| Net Cash Per Share | $0.79 |
| Equity (Book Value) | 18.97M |
| Book Value Per Share | 2.11 |
| Working Capital | 16.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.94 million and capital expenditures -$228,000, giving a free cash flow of -$2.17 million.
| Operating Cash Flow | -1.94M |
| Capital Expenditures | -228,000 |
| Free Cash Flow | -2.17M |
| FCF Per Share | -$0.21 |
Full Cash Flow StatementMargins
Gross margin is 69.04%, with operating and profit margins of 3.82% and -20.43%.
| Gross Margin | 69.04% |
| Operating Margin | 3.82% |
| Pretax Margin | -20.71% |
| Profit Margin | -20.43% |
| EBITDA Margin | 11.92% |
| EBIT Margin | 3.82% |
| FCF Margin | n/a |
Dividends & Yields
Aytu BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.40% |
| Shareholder Yield | -13.40% |
| Earnings Yield | -65.57% |
| FCF Yield | -10.47% |
Analyst Forecast
The average price target for Aytu BioPharma is $9.17, which is 351.72% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.17 |
| Price Target Difference | 351.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Aytu BioPharma has an Altman Z-Score of -2.94 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.94 |
| Piotroski F-Score | 4 |
